CN111455057A - Kit, device and method for lung cancer diagnosis - Google Patents
Kit, device and method for lung cancer diagnosis Download PDFInfo
- Publication number
- CN111455057A CN111455057A CN202010391533.2A CN202010391533A CN111455057A CN 111455057 A CN111455057 A CN 111455057A CN 202010391533 A CN202010391533 A CN 202010391533A CN 111455057 A CN111455057 A CN 111455057A
- Authority
- CN
- China
- Prior art keywords
- mir
- nucleotide sequence
- sequence number
- sequence
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kit, a device and a method for diagnosing lung cancer, wherein the kit comprises a primer and a probe for detecting the combination of an exosome long RNA marker and a miRNA marker, the long RNA marker comprises one or more of ARPC5, MBOAT2 and I L1B, and the miRNA marker comprises one or more of miR-450B-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106B-3p, miR-30e-5p, miR-4746-5p and miR-125a-5 p.
Description
Technical Field
The invention relates to the field of medical diagnosis, in particular to a diagnostic kit, a device and a method for early lung cancer.
Background
Lung cancer is one of the main cancer species in China and even in the world. According to the latest global cancer statistics in 2018, the incidence and mortality of lung cancer are the first in all cancer species. According to the Chinese tumor registration data of 2019, 390.2 ten thousand cancer cases are newly added in 2015 of China, and the death cases of cancer are about 233.8 ten thousand, wherein lung cancer is the main cause of cancer death in China. Therefore, in order to improve the diagnosis and treatment behaviors of lung cancer in China and improve the prognosis of lung cancer patients, early diagnosis becomes an important problem for diagnosis and treatment of lung cancer.
With the application of low dose helical CT, more and more imaging is shown with lung nodules (single lesions <3cm in the lung interstitium and no associated atelectasis or lymphadenopathy) being discovered. However, not all lung nodules are malignant, and identification of benign and malignant lung nodules has been a difficult point in thoracic surgical clinical diagnosis and treatment. At present, noninvasive detection means such as plasma circulating tumor cells and circulating tumor free DNA are adopted, but the detection sensitivity in early lung cancer diagnosis is not high; therefore, there is a need to develop a highly sensitive method for noninvasive early detection of lung cancer.
Disclosure of Invention
The invention provides an exosome-based reagent, an exosome-based device and an exosome-based method for non-invasive early lung cancer diagnosis.
The invention provides a kit for lung cancer diagnosis, which comprises primers and probes for detecting a long RNA marker of an exosome and miRNA marker combination, wherein the long RNA marker comprises one or more of ARPC5, MBOAT2 and I L1B, and the miRNA marker comprises one or more of miR-450B-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106B-3p, miR-30e-5p, miR-4746-5p and miR-125a-5 p.
Preferably, the marker is a combination of miR-450b-5p, let-7f-2-3p and ARPC 5.
Preferably, the marker is a combination of miR-106b-3P, miR-30e-5p and MBOAT 2.
Preferably, the marker is a combination of miR-106b-3P, miR-30e-5p, miR-3615, miR-885-5p and ARPC 5.
Preferably, the marker is a combination of miR-106B-3P, miR-125a-5p, miR-3615, miR-450B-5p and I L1B.
Preferably, the source of exosomes comprises one or more of blood, saliva and sputum.
Preferably, the primers and probes comprise:
primers and probes for detection of internal reference ACTB: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 1, the downstream primer is a nucleotide sequence shown as a sequence number 2, and the probe is a nucleotide sequence shown as a sequence number 3;
primers and probes for detection of ARPC 5: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 4, the downstream primer is a nucleotide sequence shown as a sequence number 5, and the probe is a nucleotide sequence shown as a sequence number 6;
the primer and the probe for detecting I L1B are characterized in that the upstream primer of the RNA has a nucleotide sequence shown as a sequence number 7, the downstream primer has a nucleotide sequence shown as a sequence number 8, and the probe has a nucleotide sequence shown as a sequence number 9;
primers and probes for detection of MBOAT 2: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 10, the downstream primer is a nucleotide sequence shown as a sequence number 11, and the probe is a nucleotide sequence shown as a sequence number 12;
reverse transcription primers, PCR primers and probes for detecting let-7 f-2: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 13, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 14, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 15;
reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 16, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 17, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 18;
reverse transcription primers, PCR primers and probes for detecting miR-125a-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 19, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 20, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 21;
reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 22, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 23, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 24;
reverse transcription primers, PCR primers and probes for detecting miR-3615: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 25, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 26, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 27;
reverse transcription primers, PCR primers and probes for detecting miR-450b-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 28, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 29, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 30;
reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 31, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 32, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 33;
reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 34, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 35, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 36;
reverse transcription primers, PCR primers and probes for detection of internal reference U6: the reverse transcription primer of U6 has a nucleotide sequence shown as sequence number 39, the PCR upstream primer has a nucleotide sequence shown as sequence number 37, the PCR downstream primer has a nucleotide sequence shown as sequence number 38, and the probe has a nucleotide sequence shown as sequence number 40.
In another aspect, the invention provides a device for lung cancer diagnosis, comprising primers and probes for detecting a combination of long RNA markers of exosomes, including one or more of ARPC5, MBOAT2, I L1B, and miRNA markers, including one or more of miR-450B-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106B-3p, miR-30e-5p, miR-4746-5p, miR-125a-5 p.
In another aspect, the invention provides a method for lung cancer diagnosis comprising detecting the specificity of a combination of exosome long RNA markers comprising one or more of ARPC5, MBOAT2, I L1B and miRNA markers comprising one or more of miR-450B-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106B-3p, miR-30e-5p, miR-4746-5p, miR-125a-5 p.
The invention provides a noninvasive early lung cancer diagnosis method based on exosome, which has high sensitivity and high specificity in early lung cancer and provides important value for early diagnosis of lung cancer. It is helpful for preventing and treating lung cancer in our country. Furthermore, the combination with the highest sensitivity can achieve the sensitivity of 100%, and the combination with the highest specificity can achieve the specificity of 96.67%, so that the combination has better performance.
Drawings
FIG. 1 is a ROC curve of the combination of miR-450b-5p + let-7f-2-3p + ARPC5 for detecting lung cancer.
FIG. 2 is a ROC curve of the combination of miR-106b-3P + miR-30e-5P + MBOAT2 for detecting lung cancer.
FIG. 3 is a ROC curve for the combination of miR-106b-3P + miR-30e-5P + miR-450b-5P + miR-885-5P + ARPC5 to detect lung cancer.
FIG. 4 is a ROC curve for the combination of miR-106b-3P + miR-30e-5P + miR-4746-5P + miR-885-5P + ARPC5 to detect lung cancer.
FIG. 5 is a ROC curve of the combination of miR-106b-3P + miR-30e-5P + miR-3615+ miR-885-5P + ARPC5 for detecting lung cancer.
FIG. 6 is a ROC curve of miR-106B-3P + miR-125a-5P + miR-3615+ miR-450B-5P + I L1B combination for detecting lung cancer.
Detailed Description
The Extracellular Vesicles (EVs; hereinafter Vesicles are referred to as Extracellular Vesicles) refer to vesicular bodies with a double-layer membrane structure, which are shed from cell membranes or secreted by cells, and have diameters of 30-1000nm, and mainly comprise MicroVesicles (MVs) and exosomes (exosomes), and the MicroVesicles are Vesicles shed from cell membranes after cells are activated or damaged. Extracellular vesicles are of great interest in disease diagnosis, particularly exosomes, due to their unique biological characteristics.
The exosome is a membrane vesicle with the particle size of 30-150 nm secreted into the extracellular environment after an intracellular multivesicular body and a cell membrane are fused, is an important medium for intercellular information transfer, and plays an important role in antigen presentation, apoptosis, inflammatory reaction, tumorigenesis development and metastasis processes. It is widely distributed in body fluid, including blood, saliva, urine, milk, hydrothorax and ascites, etc.; contains various inclusion substances such as DNA, RNA, protein and the like, and can be used as noninvasive diagnosis markers of various diseases such as tumors and the like. And miRNA is the most abundant nucleic acid component in exosome, so exosome miRNA has the potential of being used for early diagnosis of lung cancer.
According to the kit, the device and the method provided by the invention, the combination of long RNA and miRNA which show significant differential expression in exosome of a patient with early lung cancer is found through experimental research to be used as a marker for diagnosing early lung cancer.
In embodiments, the marker combination for diagnosing lung cancer comprises at least one long RNA and one miRNA, wherein the long RNA comprises ARPC5, MBOAT2, I L1B, and the MiRNA comprises miR-450b-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106b-3p, miR-30e-5p, miR-4746-5p and miR-125a-5 p.
In some preferred embodiments, preferred combinations are miR-450b-5P + let-7f-2-3P + ARPC5, miR-106b-3P + miR-30e-5P + MBOAT2, miR-106b-3P + miR-30e-5P + miR-450b-5P + miR-885-5P + ARPC5miR-106b-3P + miR-30e-5P + miR-4746-5P + miR-885-5P + ARPC5, miR-106b-3P + miR-30e-5P + miR-3615+ miR-885P + ARPC5 and miR-106b-3P + miR-125a-5P + miR-3615+ miR-450b-5P + I L1B.
In addition, the kit for lung cancer diagnosis of the present invention includes primers and probes for detecting the above exosome-long RNA marker. Primers and probes for detecting exosome markers include:
primers and probes for detection of internal reference ACTB: the upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 1, the downstream primer is specifically a nucleotide sequence shown as a sequence number 2, and the probe is specifically a nucleotide sequence shown as a sequence number 3;
primers and probes for detection of ARPC 5: the upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 4, the downstream primer is specifically a nucleotide sequence shown as a sequence number 5, and the probe is specifically a nucleotide sequence shown as a sequence number 6;
the primer and the probe for detecting I L1B are characterized in that an upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 7, a downstream primer is specifically a nucleotide sequence shown as a sequence number 8, and the probe is specifically a nucleotide sequence shown as a sequence number 9;
primers and probes for detection of MBOAT 2: the upstream primer of the RNA is specifically a nucleotide sequence shown as a sequence number 10, the downstream primer is specifically a nucleotide sequence shown as a sequence number 11, and the probe is specifically a nucleotide sequence shown as a sequence number 12;
reverse transcription primers, PCR primers and probes for detecting let-7 f-2: the reverse transcription primer is specifically a nucleotide sequence shown as a sequence number 13, the PCR upstream primer is specifically a nucleotide sequence shown as a sequence number 14, the downstream primer is specifically a nucleotide sequence shown as a sequence number 41, and the probe is specifically a nucleotide sequence shown as a sequence number 15;
reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 16, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 17, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 18;
reverse transcription primers, PCR primers and probes for detecting miR-125a-5 p: the reverse transcription primer is specifically a nucleotide sequence shown as a sequence number 19, the PCR upstream primer is specifically a nucleotide sequence shown as a sequence number 20, the PCR downstream primer is specifically a nucleotide sequence shown as a sequence number 41, and the probe is specifically a nucleotide sequence shown as a sequence number 21;
reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 22, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 23, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 24;
reverse transcription primers, PCR primers and probes for detecting miR-3615: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 25, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 26, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 27;
reverse transcription primers, PCR primers and probes for detecting miR-450b-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 28, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 29, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 30;
reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown as a sequence number 31, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 32, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 33;
reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer is specifically shown as a nucleotide sequence shown in a sequence number 34, the PCR upstream primer is specifically shown as a nucleotide sequence shown in a sequence number 35, the downstream primer is specifically shown as a nucleotide sequence shown in a sequence number 41, and the probe is specifically shown as a nucleotide sequence shown in a sequence number 36;
reverse transcription primers, PCR primers and probes for detection of internal reference U6: the reverse transcription primer of U6 is specifically shown as a nucleotide sequence shown as a sequence number 39, the PCR upstream primer is specifically shown as a nucleotide sequence shown as a sequence number 37, the downstream primer is specifically shown as a nucleotide sequence shown as a sequence number 38, and the probe is specifically shown as a nucleotide sequence shown as a sequence number 40. The nucleotide sequences of the primers and probes are shown in Table 1.
TABLE 1
Further, the source of exosomes includes one or more of blood, saliva, and sputum.
The kit, the device and the method are suitable for individuals, such as people at high risk of lung cancer, normal individuals and patients after lung cancer operation.
The technical solution of the present invention will be described in detail with reference to the following embodiments, which are a part of the embodiments of the present invention, but not all of them. Other embodiments, which can be derived by one of ordinary skill in the art from the embodiments of the present invention without creative efforts, are within the protection scope of the present invention.
In order to screen an exosome marker related to diagnosis of colon lung cancer, 50 cases of early lung cancer patients and 72 cases of controls respectively take blood of not less than 10ml and separate plasma, the blood is used for separating exosomes in the plasma by a classical ultracentrifugation method and extracting RNA, and the obtained RNA is respectively subjected to RNA library construction and sequencing. The data obtained were analyzed bioinformatically to compare differentially expressed RNA in early lung cancer patients and controls. These exosome-derived RNA-level markers can be used for early diagnosis of lung cancer.
Further directed to the method wherein the RNA marker is further analyzed by the following steps: (1) collecting body fluid samples (including blood, sputum and saliva) of individuals to be detected; (2) isolating exosomes in the body fluid; (3) detecting the expression level of target RNA by using a two-step method; (4) normalizing the expression level of the detection target RNA by using the reference gene; (5) substituting the normalized gene expression level into a judgment model to obtain an output value; (6) and judging whether the individual to be detected is lung cancer or not according to the output value of the model and the judgment threshold value.
The kit comprises a PCR primer, a probe and a standard substance for detecting the long RNA marker of the exosome and a two-step detection system of PCR.
The method comprises the steps of selecting an internal reference β -Actin (ACTB) to carry out long RNA quantification, and taking U6 as the internal reference to carry out miRNA quantification, wherein the expression level of a marker is calculated by using a quantitative formula 2 delta Ct according to a detection Ct value in the quantification of target RNA in the case of selecting a reference, and after the expression level of the target RNA is obtained, the accuracy of detecting lung cancer by using single RNA or combining a plurality of RNAs is evaluated by using a ROC characteristic curve and AUC.
Example 1 screening of exosome mRNA and L ncRNA markers associated with early lung cancer based on high throughput sequencing
In order to screen an exosome marker related to early lung cancer diagnosis, 50 cases of patients 72 and controls for early lung cancer diagnosis are respectively selected, blood is taken to be not less than 10ml, plasma is separated, exosome in the plasma is separated by a classical ultracentrifugation method, RNA is extracted by a qiagen miRNeasy mini kit, and the obtained RNA is subjected to micro-enucleation ribosome strand specific RNA library-building sequencing and small RNA library-building sequencing. The obtained data were analyzed by bioinformatics, and long RNAs and mirnas differentially expressed in early lung cancer patients and controls were compared to obtain long RNAs with significant differences as shown in table 2 below. These exosome-derived RNA-level markers can be used for early diagnosis of lung cancer.
TABLE 2
Example 2 fluorescent quantitation PCR platform based miRNA detection system
1. miRNA reverse transcription reaction system
miRNA reverse transcription reagents, enzymes and oligdT were purchased from TAKARA, standards were synthesized from Shanghai Yinxie substrate, and primers with reversed specificity were synthesized by Suzhou Hongyu. A20 ul reverse transcription system was used, as shown in Table 3 below.
TABLE 3
2. PCR reaction system
The PCR reaction mixture was purchased from TAKARA, the upstream primer, the probe, i.e., the universal downstream primer, was synthesized by Honghong, Suzhou, and the fluorescent quantitative PCR instrument was ABI 7500. The PCR reaction system is shown in Table 4 below:
TABLE 4
The PCR procedure was 95 ℃ for 10min, (95 ℃ for 15s, 55 ℃ for 30s) for 15 cycles without fluorescence collection, and (95 ℃ for 15s, 55 ℃ for 30s) for 35 cycles with fluorescence collection.
Example 3 fluorescent quantitative PCR platform based mRNA and L ncRNA detection system
1. Reverse transcription of mRNA and L ncRNA
PrimeScript from takara was usedTMRT reagent Kit (Perfect Real Time) and Premix Ex TaqTM(Probe qPCR) kit for reverse transcription and qPCR detection.
Preparing a reverse transcription reaction system (reaction liquid preparation) according to the following componentsPrepared on ice), then put into a PCR instrument for reaction under the reaction conditions of 37 ℃ for 60min, 85 ℃ for 5s and 12 ℃ infinity, and 50ul DEPC-H is added after the reverse transcription is finished2Diluting with O, taking 3ul as a template, and carrying out PCR reaction. The reverse transcription reaction system is shown in Table 5 below.
TABLE 5
2. mRNA and L ncRNA qPCR
The qPCR reaction system was prepared as follows (reaction solution was prepared on ice) and a no template control was set as a negative control. Then, the mixture was put into a real-time fluorescence PCR apparatus (ABI7500) to perform amplification detection under the following reaction conditions. The qPCR reaction system is shown in table 6 below and the qPCR reaction conditions are shown in table 7 below.
TABLE 6
TABLE 7
Example 4 evaluation of Effect of Single-marker Lung cancer early diagnosis detection
1. Sample collection
10ml of blood of control samples of early stage (stage I and stage II) lung nodule lung cancer patients, benign lung nodule patients, healthy persons, etc. diagnosed in hospitals were collected and separated into plasma.
2. Exosome RNA extraction
Plasma exosome separation is carried out by ultracentrifugation or Exosuurur of Echobiotech (Beijing Enzekangtai), long RNA in exosome is extracted from the separated exosome by a Qiagen MiReasy mini kit, RNA concentration and quality are detected by Agilent 2100, and the RNA concentration is recorded.
3. RNA two-step detection system
A two-step method detection system based on mRNA of a PCR platform in example 1 is adopted to detect plasma exosome mRNA and L ncRNA of 30 cases and 30 cases of control samples (healthy people and benign nodules) of early-stage lung cancer patients, the Ct value of target long RNA is detected, and the relative expression quantity is calculated according to the Ct value and a relative quantitative formula.
4. Evaluation of exosome RNA single marker diagnosis early lung cancer performance
As shown in the table below, the Ct value of a target gene is detected for plasma exosomes of 30 and 30 control samples (healthy people and benign lesions) of early lung cancer patients, wherein long RNA is referenced by internal reference β -Actin, miRNA is referenced by internal reference U6, the relative expression level of RNA is obtained according to the Ct value, the fold change of the relative expression quantity of a combined marker is calculated by using a relative quantitative formula value, and further the relative expression quantity of RNA is obtained, the detection result is statistically analyzed by using R language, the performance evaluation of a single marker is shown in the table 8 below, wherein miR-450b-5p and miR-3615 have good sensitivity, and let-7f-2-3p has good specificity.
TABLE 8
Example 5 evaluation of Long RNA and miRNA in combination for early diagnosis of Lung cancer
1. Three marker combination performance evaluation
Relative expression levels of each long RNA were calculated according to the method described in example 3, and the three marker combinations were trained using logistic regression, and the combinations with AUC of 0.76 or higher for the three marker combinations were obtained as shown in table 9 below. The miR-450b-5p + let-7f-2-3p + ARPC5 combination has the optimal performance, the accuracy is 76.67%, and the AUC curves are respectively shown in figure 1; the miR-106b-3P + miR-30e-5P + MBOAT2 has better specificity (80%), and the AUC curve is shown in the following figure 1.
TABLE 9
2. Five marker combination performance evaluation
The relative expression of each long RNA was calculated as in example 3, and the five marker combinations were trained using logistic regression, resulting in a combination with AUC above 0.85 as shown in Table 10 below, where two combinations of miR-106B-3P + miR-30e-5P + miR-450B-5P + miR-885-5P + ARPC5 and miR-106B-3P + miR-30e-5P + miR-4746-5P + miR-885-5P + ARPC5 had good sensitivity, 93.33% and 100% respectively, the AUC curves of which are shown in FIG. 3 and FIG. 4, and miR-106B-3P + miR-30e-5P + miR-3615+ miR-885P + ARPC5 and miR-106B-3P + miR-125a-5P + miR-3615+ miR-450B-5P + I L1B had good specificity, 96% and 90% specificity curves of which are shown in FIG. 6.96% and 6.
The data show that the exosome-based noninvasive early lung cancer diagnosis method has high sensitivity and high specificity in early lung cancer, and provides important value for early diagnosis of lung cancer. It is helpful for preventing and treating lung cancer in our country. The combination with the highest sensitivity can achieve the sensitivity of 100%, and the combination with the highest specificity can achieve the specificity of 96.67%, so that the method has better performance.
The preferred embodiments of the invention disclosed above are intended to be illustrative only. The preferred embodiments are not intended to be exhaustive or to limit the invention to the precise embodiments disclosed. Obviously, many modifications and variations are possible in light of the above teaching. The embodiments were chosen and described in order to best explain the principles of the invention and the practical application, to thereby enable others skilled in the art to best utilize the invention. The invention is limited only by the claims and their full scope and equivalents.
Sequence listing
<110> tumor hospital of Chinese medical science institute
<120> kit, device and method for lung cancer diagnosis
<130>2000003
<160>41
<170>SIPOSequenceListing 1.0
<210>1
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
cctcgccttt gccgatcc 18
<210>2
<211>17
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
catgcccacc atcacgc 17
<210>3
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
acccgccgcc agctcacca 19
<210>4
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
cgaggtggac tcctgcct 18
<210>5
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
ctgcccggtc cttcactg 18
<210>6
<211>25
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
actcttggtg ttgatagggg ggttc 25
<210>7
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>7
gccctaaaca gatgaagtgc tc 22
<210>8
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>8
<210>9
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>9
tctgccctct ggatggcggc at 22
<210>10
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>10
tctgctgatt tttcaggccc a 21
<210>11
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>11
<210>12
<211>27
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>12
tggcttgcga aattcatgat gggatgt 27
<210>13
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>13
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacggaaag 50
<210>14
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>14
agcgcctata cagtctactg t 21
<210>15
<211>24
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>15
tcgcactgga tacgacggaa agac 24
<210>16
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>16
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgcagca 50
<210>17
<211>17
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>17
accgcactgt gggtact 17
<210>18
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>18
tcgcactgga tacgacgcag ca 22
<210>19
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>19
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactcacag 50
<210>20
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>20
<210>21
<211>24
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>21
tcgcactgga tacgactcac aggt 24
<210>22
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>22
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccttcca 50
<210>23
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>23
accgctgtaa acatccttga c 21
<210>24
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>24
tcgcactgga tacgaccttc ca 22
<210>25
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>25
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgagccg 50
<210>26
<211>17
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>26
cctctctcgg ctcctcg 17
<210>27
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>27
tcgcactgga tacgacgagc cg 22
<210>28
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>28
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactattca 50
<210>29
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>29
tccgcttttg caatatgttc c 21
<210>30
<211>26
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>30
ttcgcactgg atacgactat tcagga 26
<210>31
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>31
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactctgca 50
<210>32
<211>17
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>32
ccggtcccag gagaacc 17
<210>33
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>33
tcgcactgga tacgactctg ca 22
<210>34
<211>50
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>34
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacagaggc 50
<210>35
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>35
<210>36
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>36
tcgcactgga tacgacagag gc 22
<210>37
<211>17
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>37
ctcgcttcgg cagcaca 17
<210>38
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>38
<210>39
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>39
<210>40
<211>25
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>40
agaagattag catggcccct gcgca 25
<210>41
<211>16
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>41
gtgcagggtc cgaggt 16
Claims (9)
1. A kit for lung cancer diagnosis, comprising primers and probes for detecting a combination of long RNA markers of exosomes, including one or more of ARPC5, MBOAT2, I L1B, and miRNA markers, including one or more of miR-450B-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106B-3p, miR-30e-5p, miR-4746-5p, miR-125a-5 p.
2. The kit of claim 1, wherein the marker is a combination of miR-450b-5p, let-7f-2-3p, and ARPC 5.
3. The kit of claim 1, wherein the marker is a combination of miR-106b-3P, miR-30e-5p and MBOAT 2.
4. The kit of claim 1, wherein the marker is a combination of miR-106b-3P, miR-30e-5p, miR-3615, miR-885-5p, and ARPC 5.
5. The kit of claim 1, wherein the marker is a combination of miR-106B-3P, miR-125a-5p, miR-3615, miR-450B-5p, and I L1B.
6. The kit of claim 1, wherein the source of exosomes comprises one or more of blood, saliva, and sputum.
7. The kit of claim 1, wherein the primers and probes comprise:
primers and probes for detection of internal reference ACTB: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 1, the downstream primer is a nucleotide sequence shown as a sequence number 2, and the probe is a nucleotide sequence shown as a sequence number 3;
primers and probes for detection of ARPC 5: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 4, the downstream primer is a nucleotide sequence shown as a sequence number 5, and the probe is a nucleotide sequence shown as a sequence number 6;
the primer and the probe for detecting I L1B are characterized in that the upstream primer of the RNA has a nucleotide sequence shown as a sequence number 7, the downstream primer has a nucleotide sequence shown as a sequence number 8, and the probe has a nucleotide sequence shown as a sequence number 9;
primers and probes for detection of MBOAT 2: the upstream primer of the RNA is a nucleotide sequence shown as a sequence number 10, the downstream primer is a nucleotide sequence shown as a sequence number 11, and the probe is a nucleotide sequence shown as a sequence number 12;
reverse transcription primers, PCR primers and probes for detecting let-7 f-2: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 13, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 14, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 15;
reverse transcription primers, PCR primers and probes for detecting miR-106b-3 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 16, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 17, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 18;
reverse transcription primers, PCR primers and probes for detecting miR-125a-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 19, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 20, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 21;
reverse transcription primers, PCR primers and probes for detecting miR-30e-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 22, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 23, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 24;
reverse transcription primers, PCR primers and probes for detecting miR-3615: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 25, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 26, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 27;
reverse transcription primers, PCR primers and probes for detecting miR-450b-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 28, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 29, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 30;
reverse transcription primers, PCR primers and probes for detecting miR-4746-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 31, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 32, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 33;
reverse transcription primers, PCR primers and probes for detecting miR-885-5 p: the reverse transcription primer is shown as a nucleotide sequence in a sequence number 34, the PCR upstream primer is shown as a nucleotide sequence in a sequence number 35, the PCR downstream primer is shown as a nucleotide sequence in a sequence number 41, and the probe is shown as a nucleotide sequence in a sequence number 36;
reverse transcription primers, PCR primers and probes for detection of internal reference U6: the reverse transcription primer of U6 has a nucleotide sequence shown as sequence number 39, the PCR upstream primer has a nucleotide sequence shown as sequence number 37, the PCR downstream primer has a nucleotide sequence shown as sequence number 38, and the probe has a nucleotide sequence shown as sequence number 40.
8. A device for lung cancer diagnosis comprising primers and probes for detecting a combination of long RNA markers of exosomes, including one or more of ARPC5, MBOAT2, I L1B, and miRNA markers, including one or more of miR-450B-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106B-3p, miR-30e-5p, miR-4746-5p, miR-125a-5 p.
9. A method for lung cancer diagnosis comprising detecting the specificity of a combination of exosome long RNA markers comprising one or more of ARPC5, MBOAT2, I L1B and miRNA markers comprising one or more of miR-450B-5p, miR-let-7f, miR-3615, miR-885-5p, miR-106B-3p, miR-30e-5p, miR-4746-5p, miR-125a-5 p.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210144616.0A CN114214422B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202111108621.8A CN113930505B (en) | 2020-03-30 | 2020-05-11 | Kit and device for lung cancer diagnosis |
| CN202210144425.4A CN114214419B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, MBOAT2 and the like in lung cancer diagnosis |
| CN202111109658.2A CN113774138B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144490.7A CN114410794B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144440.9A CN114214421B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, ARPC5 and the like in lung cancer diagnosis |
| CN202111109657.8A CN113801936B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144442.8A CN114231638B (en) | 2020-03-30 | 2020-05-11 | Application of exosome-7 f-2-3p, ARPC5 and the like in lung cancer diagnosis |
| CN202210144431.XA CN114214420B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106B-3P, IL B and the like in lung cancer diagnosis |
| CN202210144702.1A CN114214423B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-30e-5p, IL1B and the like in lung cancer diagnosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010262401X | 2020-03-30 | ||
| CN202010262401 | 2020-03-30 |
Related Child Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210144440.9A Division CN114214421B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, ARPC5 and the like in lung cancer diagnosis |
| CN202210144490.7A Division CN114410794B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202111108621.8A Division CN113930505B (en) | 2020-03-30 | 2020-05-11 | Kit and device for lung cancer diagnosis |
| CN202210144616.0A Division CN114214422B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144702.1A Division CN114214423B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-30e-5p, IL1B and the like in lung cancer diagnosis |
| CN202210144442.8A Division CN114231638B (en) | 2020-03-30 | 2020-05-11 | Application of exosome-7 f-2-3p, ARPC5 and the like in lung cancer diagnosis |
| CN202111109658.2A Division CN113774138B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144431.XA Division CN114214420B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106B-3P, IL B and the like in lung cancer diagnosis |
| CN202210144425.4A Division CN114214419B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, MBOAT2 and the like in lung cancer diagnosis |
| CN202111109657.8A Division CN113801936B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111455057A true CN111455057A (en) | 2020-07-28 |
| CN111455057B CN111455057B (en) | 2021-10-26 |
Family
ID=71674744
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111109657.8A Active CN113801936B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144442.8A Active CN114231638B (en) | 2020-03-30 | 2020-05-11 | Application of exosome-7 f-2-3p, ARPC5 and the like in lung cancer diagnosis |
| CN202210144425.4A Active CN114214419B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, MBOAT2 and the like in lung cancer diagnosis |
| CN202210144616.0A Active CN114214422B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144702.1A Active CN114214423B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-30e-5p, IL1B and the like in lung cancer diagnosis |
| CN202111109658.2A Active CN113774138B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202010391533.2A Active CN111455057B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144490.7A Active CN114410794B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144431.XA Active CN114214420B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106B-3P, IL B and the like in lung cancer diagnosis |
| CN202210144440.9A Active CN114214421B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, ARPC5 and the like in lung cancer diagnosis |
| CN202111108621.8A Active CN113930505B (en) | 2020-03-30 | 2020-05-11 | Kit and device for lung cancer diagnosis |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111109657.8A Active CN113801936B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
| CN202210144442.8A Active CN114231638B (en) | 2020-03-30 | 2020-05-11 | Application of exosome-7 f-2-3p, ARPC5 and the like in lung cancer diagnosis |
| CN202210144425.4A Active CN114214419B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, MBOAT2 and the like in lung cancer diagnosis |
| CN202210144616.0A Active CN114214422B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144702.1A Active CN114214423B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-30e-5p, IL1B and the like in lung cancer diagnosis |
| CN202111109658.2A Active CN113774138B (en) | 2020-03-30 | 2020-05-11 | Kit, device and method for lung cancer diagnosis |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210144490.7A Active CN114410794B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106b-3P, ARPC5 in lung cancer diagnosis |
| CN202210144431.XA Active CN114214420B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-106B-3P, IL B and the like in lung cancer diagnosis |
| CN202210144440.9A Active CN114214421B (en) | 2020-03-30 | 2020-05-11 | Application of exosome miR-3615, ARPC5 and the like in lung cancer diagnosis |
| CN202111108621.8A Active CN113930505B (en) | 2020-03-30 | 2020-05-11 | Kit and device for lung cancer diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (11) | CN113801936B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102272330A (en) * | 2009-02-23 | 2011-12-07 | 博奥生物有限公司 | Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival |
| CN103484550A (en) * | 2013-09-30 | 2014-01-01 | 中国科学院上海微系统与信息技术研究所 | MicroRNA biological markers for early lung cancer diagnosis and application thereof |
| CA2892529A1 (en) * | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20160130656A1 (en) * | 2014-07-14 | 2016-05-12 | Allegro Diagnostics Corp. | Methods for evaluating lung cancer status |
| US20160312310A1 (en) * | 2008-12-15 | 2016-10-27 | Micromedmark Biotech Co., Ltd. | Serum or plasma microrna as biomarkers for non-small cell lung cancer |
| CN108998530A (en) * | 2018-08-31 | 2018-12-14 | 昆明医科大学第附属医院 | Lung cancer raises long-chain non-coding RNA marker and its application |
| CN111378758A (en) * | 2020-03-30 | 2020-07-07 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN111424093A (en) * | 2020-03-30 | 2020-07-17 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN111676291A (en) * | 2020-07-14 | 2020-09-18 | 徐州医科大学 | miRNA marker for lung cancer risk assessment |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305811A1 (en) * | 2005-07-27 | 2011-04-06 | Oncotherapy Science, Inc. | Method of diagnosing smal cell lung cancer |
| US20090047689A1 (en) * | 2007-06-20 | 2009-02-19 | John Kolman | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma |
| WO2009080437A1 (en) * | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
| GB2463401B (en) * | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
| EP2470897A4 (en) * | 2009-08-28 | 2013-05-29 | Asuragen Inc | Mirna biomarkers of lung disease |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| CN103476947A (en) * | 2011-03-02 | 2013-12-25 | 格路福生物制药公司 | Enhanced biodistribution of oligomers |
| US20140243403A1 (en) * | 2011-06-03 | 2014-08-28 | The General Hospital Corporation | Treating colorectal, pancreatic, and lung cancer |
| CN103505743A (en) * | 2012-06-21 | 2014-01-15 | 北京命码生科科技有限公司 | Cell micro-particles containing functional microRNA/siRNA and application thereof |
| CN103651811A (en) * | 2012-09-07 | 2014-03-26 | 北京命码生科科技有限公司 | Human milk micro ribonucleic acids and application thereof |
| US20160022840A1 (en) * | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| BR112015026095A8 (en) * | 2013-04-15 | 2020-01-21 | Regeneron Pharma | method of using tumor-responsive biomarkers, method for selecting at least one anti-tumor drug, composition comprising an anti-tumor drug, combination to control the dosage of an anti-tumor drug, use of tumor-responsive biomarkers |
| WO2015050891A2 (en) * | 2013-10-02 | 2015-04-09 | Hitachi Chemical Company Ltd. | Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens |
| KR102511402B1 (en) * | 2014-06-18 | 2023-03-17 | 국립연구개발법인 고쿠리츠간켄큐센터 | Kit or device for detecting lung cancer, and lung cancer detection method |
| US11053545B2 (en) * | 2015-09-08 | 2021-07-06 | The Translational Genomics Research Institute | Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries |
| CN105675774B (en) * | 2016-01-19 | 2018-10-23 | 上海交通大学 | The preparation method of saliva excretion body and its application in molecule diagnosis |
| EP3443001A4 (en) * | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| US10314855B2 (en) * | 2017-01-23 | 2019-06-11 | Trustees Of Boston University | Methods relating to lung cancer |
| CN106755544A (en) * | 2017-03-10 | 2017-05-31 | 大连医科大学附属第医院 | MiRNA marker and application in a kind of serum excretion body related to adenocarcinoma of lung early diagnosis |
| CN110452981A (en) * | 2017-06-07 | 2019-11-15 | 深圳市海普洛斯生物科技有限公司 | The kit of early screening of lung cancer based on peripheral blood |
| US11359247B2 (en) * | 2017-07-31 | 2022-06-14 | Massachusetts Institute Of Technology | High performance multi-input microRNA sensors and uses thereof |
| CN113604564A (en) * | 2017-08-14 | 2021-11-05 | 江苏为真生物医药技术股份有限公司 | Method for detecting exosome-associated microRNA (ribonucleic acid) molecules |
| WO2019163900A1 (en) * | 2018-02-22 | 2019-08-29 | 国立大学法人大阪大学 | Analysis/diagnosis method utilizing rna modification |
| CN110872628A (en) * | 2018-08-30 | 2020-03-10 | 杨昆德 | Use of extracellular vesicles as biomarkers for the preparation of kits |
| CN109971853A (en) * | 2019-03-14 | 2019-07-05 | 中国科学院北京基因组研究所 | One kind molecular marker relevant to Diagnosis of Non-Small Cell Lung and its application |
| CN110699457B (en) * | 2019-10-30 | 2022-11-25 | 深圳瑞科生物科技有限公司 | Primer group and kit for detecting lung cancer |
-
2020
- 2020-05-11 CN CN202111109657.8A patent/CN113801936B/en active Active
- 2020-05-11 CN CN202210144442.8A patent/CN114231638B/en active Active
- 2020-05-11 CN CN202210144425.4A patent/CN114214419B/en active Active
- 2020-05-11 CN CN202210144616.0A patent/CN114214422B/en active Active
- 2020-05-11 CN CN202210144702.1A patent/CN114214423B/en active Active
- 2020-05-11 CN CN202111109658.2A patent/CN113774138B/en active Active
- 2020-05-11 CN CN202010391533.2A patent/CN111455057B/en active Active
- 2020-05-11 CN CN202210144490.7A patent/CN114410794B/en active Active
- 2020-05-11 CN CN202210144431.XA patent/CN114214420B/en active Active
- 2020-05-11 CN CN202210144440.9A patent/CN114214421B/en active Active
- 2020-05-11 CN CN202111108621.8A patent/CN113930505B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160312310A1 (en) * | 2008-12-15 | 2016-10-27 | Micromedmark Biotech Co., Ltd. | Serum or plasma microrna as biomarkers for non-small cell lung cancer |
| CN102272330A (en) * | 2009-02-23 | 2011-12-07 | 博奥生物有限公司 | Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival |
| CA2892529A1 (en) * | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20180000910A1 (en) * | 2012-11-26 | 2018-01-04 | Modernatx, Inc. | Terminally modified rna |
| CN103484550A (en) * | 2013-09-30 | 2014-01-01 | 中国科学院上海微系统与信息技术研究所 | MicroRNA biological markers for early lung cancer diagnosis and application thereof |
| US20160130656A1 (en) * | 2014-07-14 | 2016-05-12 | Allegro Diagnostics Corp. | Methods for evaluating lung cancer status |
| CN108998530A (en) * | 2018-08-31 | 2018-12-14 | 昆明医科大学第附属医院 | Lung cancer raises long-chain non-coding RNA marker and its application |
| CN111378758A (en) * | 2020-03-30 | 2020-07-07 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN111424093A (en) * | 2020-03-30 | 2020-07-17 | 中国医学科学院肿瘤医院 | Kit, device and method for lung cancer diagnosis |
| CN111676291A (en) * | 2020-07-14 | 2020-09-18 | 徐州医科大学 | miRNA marker for lung cancer risk assessment |
Non-Patent Citations (5)
| Title |
|---|
| ANGEL JUAREZ-FLORES等: "Squamous cell carcinoma of the lung: gene expression and network analysis during carcinogenesis", 《INT J CLIN EXP MED》 * |
| 周斯悦等: "外泌体在肺癌发病机制及诊疗中的研究进展", 《国际检验医学杂志》 * |
| 徐高俊等: "MicroRNA-30e-5p通过下调泛素特异性蛋白酶22抑制非小细胞肺癌的发生和发展", 《第二军医大学学报》 * |
| 李元滨等: "中西医联合治疗对晚期NSCLC miRNA表达谱的影响", 《中国中西医结合杂志》 * |
| 王琳等: "血清微小RNA在肺癌诊断及预后评估中的作用", 《上海交通大学学报(医学版)》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114214420B (en) | 2023-06-23 |
| CN113930505A (en) | 2022-01-14 |
| CN114214420A (en) | 2022-03-22 |
| CN114214422A (en) | 2022-03-22 |
| CN114214421B (en) | 2023-06-23 |
| CN114214423A (en) | 2022-03-22 |
| CN113774138A (en) | 2021-12-10 |
| CN114214423B (en) | 2023-06-27 |
| CN114231638B (en) | 2023-06-27 |
| CN113801936A (en) | 2021-12-17 |
| CN114231638A (en) | 2022-03-25 |
| CN114214419B (en) | 2023-06-27 |
| CN114214419A (en) | 2022-03-22 |
| CN113774138B (en) | 2022-03-18 |
| CN114214421A (en) | 2022-03-22 |
| CN111455057B (en) | 2021-10-26 |
| CN114410794A (en) | 2022-04-29 |
| CN113930505B (en) | 2022-04-19 |
| CN113801936B (en) | 2022-04-19 |
| CN114214422B (en) | 2023-06-27 |
| CN114410794B (en) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111424093B (en) | Kit, device and method for lung cancer diagnosis | |
| CN114277145B (en) | Application of exosomes ARPC5, FHL1 and the like in lung cancer diagnosis | |
| CN111455057B (en) | Kit, device and method for lung cancer diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |